Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.

IF 2.2 4区医学 Q3 ONCOLOGY Cancer Causes & Control Pub Date : 2024-09-21 DOI:10.1007/s10552-024-01911-2

Adomas Ladukas, Ausvydas Patasius, Marius Kincius, Mingaile Drevinskaite, Justinas Jonusas, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte

{"title":"Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.","authors":"Adomas Ladukas, Ausvydas Patasius, Marius Kincius, Mingaile Drevinskaite, Justinas Jonusas, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte","doi":"10.1007/s10552-024-01911-2","DOIUrl":null,"url":null,"abstract":"Purpose: The objective of our study was to evaluate bladder cancer risk among Lithuanian type 2 diabetes mellitus (T2DM) patients and the effect of antihyperglycemic therapy on bladder cancer risk.Methods: We analyzed bladder cancer risk in a cohort of patients who were diagnosed with T2DM between 2001 and 2012 in Lithuania. Bladder cancer risk in four groups of antihyperglycemic medication users (insulin-only, metformin-only, sulfonylurea-only, and pioglitazone ± any other drug) was also assessed. Standardized incidence ratios for bladder cancer were calculated.Results: A total of 76,818 patients (28,762 males and 48,056 females) with T2DM were included in the final cohort. In the whole cohort of diabetic patients, 277 bladder cancer cases were observed, compared to 232.75 expected cases, according to bladder cancer rates in the general population (Standardized Incidence Ratio 1.19; 95% Confidence Interval: 1.06-1.34). Higher risk of bladder cancer was found in both men and women; however, in women the risk increase was not statistically significant. We found higher risk of bladder cancer in patients of both sexes diagnosed with T2DM at the age of 50-79 years and also in all groups of different antihyperglycemic medication users.Conclusion: T2DM was associated with increased risk of bladder cancer.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Causes & Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10552-024-01911-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The objective of our study was to evaluate bladder cancer risk among Lithuanian type 2 diabetes mellitus (T2DM) patients and the effect of antihyperglycemic therapy on bladder cancer risk.

Methods: We analyzed bladder cancer risk in a cohort of patients who were diagnosed with T2DM between 2001 and 2012 in Lithuania. Bladder cancer risk in four groups of antihyperglycemic medication users (insulin-only, metformin-only, sulfonylurea-only, and pioglitazone ± any other drug) was also assessed. Standardized incidence ratios for bladder cancer were calculated.

Results: A total of 76,818 patients (28,762 males and 48,056 females) with T2DM were included in the final cohort. In the whole cohort of diabetic patients, 277 bladder cancer cases were observed, compared to 232.75 expected cases, according to bladder cancer rates in the general population (Standardized Incidence Ratio 1.19; 95% Confidence Interval: 1.06-1.34). Higher risk of bladder cancer was found in both men and women; however, in women the risk increase was not statistically significant. We found higher risk of bladder cancer in patients of both sexes diagnosed with T2DM at the age of 50-79 years and also in all groups of different antihyperglycemic medication users.

Conclusion: T2DM was associated with increased risk of bladder cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2 型糖尿病患者罹患膀胱癌的风险：立陶宛一项基于人群的回顾性队列研究。

目的：我们的研究旨在评估立陶宛 2 型糖尿病 (T2DM) 患者罹患膀胱癌的风险，以及降糖治疗对膀胱癌风险的影响：我们分析了立陶宛 2001 年至 2012 年期间确诊为 T2DM 患者的膀胱癌风险。我们还评估了四组降糖药物使用者（仅使用胰岛素、仅使用二甲双胍、仅使用磺脲类药物以及使用吡格列酮和其他药物）的膀胱癌风险。计算了膀胱癌的标准化发病率：共有 76,818 名 T2DM 患者（男性 28,762 人，女性 48,056 人）被纳入最终队列。在整个糖尿病患者队列中，共观察到 277 例膀胱癌病例，而根据普通人群的膀胱癌发病率，预期病例数为 232.75 例（标准化发病率比 1.19；95% 置信区间：1.06-1.34）。男性和女性罹患膀胱癌的风险都较高；不过，女性罹患膀胱癌的风险增加在统计学上并不显著。我们发现，在 50-79 岁被诊断出患有 T2DM 的男女患者中，以及在所有使用不同降糖药物的人群中，膀胱癌的风险都较高：结论：T2DM 与膀胱癌风险增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Causes & Control 医学-公共卫生、环境卫生与职业卫生

CiteScore

3.90

自引率

4.30%

发文量

130

审稿时长

6.6 months

期刊介绍： Cancer Causes & Control is an international refereed journal that both reports and stimulates new avenues of investigation into the causes, control, and subsequent prevention of cancer. By drawing together related information published currently in a diverse range of biological and medical journals, it has a multidisciplinary and multinational approach. The scope of the journal includes: variation in cancer distribution within and between populations; factors associated with cancer risk; preventive and therapeutic interventions on a population scale; economic, demographic, and health-policy implications of cancer; and related methodological issues. The emphasis is on speed of publication. The journal will normally publish within 30 to 60 days of acceptance of manuscripts. Cancer Causes & Control publishes Original Articles, Reviews, Commentaries, Opinions, Short Communications and Letters to the Editor which will have direct relevance to researchers and practitioners working in epidemiology, medical statistics, cancer biology, health education, medical economics and related fields. The journal also contains significant information for government agencies concerned with cancer research, control and policy.